跌超70%，300630退市

Group 1 - The core point of the news is the significant decline in the stock price of Puli Pharmaceutical (普利制药), which dropped over 70% due to financial fraud allegations and subsequent delisting announcements [1][3][4] - Puli Pharmaceutical's stock and convertible bonds will be delisted following a notice from the Shenzhen Stock Exchange due to financial misconduct, with the last trading day expected to be May 21, 2025 [1][3] - The company reported a total of 669 million yuan in false profits for the years 2021 and 2022, which accounted for 73.83% of the total profits disclosed for those years [3][4] Group 2 - The ST (Special Treatment) sector experienced a wave of stock price declines, with over 30 stocks hitting the daily limit down, indicating a broader market reaction to the news of Puli Pharmaceutical [3][4] - Several other companies, including Lihang Technology and Gengxing Co., announced temporary suspensions and risk warnings, indicating potential delisting risks for multiple firms [3][5] - The PEEK material sector saw a rise in stock prices, with companies like Xinhang New Materials and Kent Co. increasing by over 13%, suggesting a divergence in market performance amid the broader downturn [6][8]